IESET.
Hypotheses·regulatory·precautionary_regulation_innovation_productivity_gap_eu_us

Precautionary-principle-based regulation in the EU produces a three-order causal chain relative to the US regulatory baseline.

FIRST-ORDER: environmental, privacy, consumer-safety, and pharma- safety protections are codified and (largely) enforced — citizens receive measurable protection from harms targeted by each regulation (REACH substances registered; GDPR breach notifications required; AI Act high-risk systems audited; EMA pharma-safety signals maintained). This is an acknowledged policy success for citizens. SECOND-ORDER: compliance costs rise, especially for small and medium firms; EU single-market fragmentation persists because member states transpose differentially; product-launch timing in the EU lags the US. THIRD-ORDER: R&D investment and firm formation relocate (pharmaceutical product launches in US then EU; AI and biotech unicorn formation; venture funding per capita gap); EU-US productivity and per-capita income gap widens. Cases: GDPR 2018, REACH 2007-2018, AI Act 2024, EMA vs FDA drug approval timing, Digital Markets Act / Digital Services Act 2022- 2024.

PARTIALengine/runs/precautionary_regulation_innovation_productivity_gap_eu_us

PARTIAL — ATT=+8.614e+04, p=0, N=260, treated_countries=1; claim direction ambiguous

confidence cueThe result is useful, but not decisive. Treat it as a clue, not a settled conclusion.

policy briefMixed or noisy

In ordinary language

Over a long period, do more market-oriented institutions translate into higher income or productivity, once the comparison looks beyond a single success story?

plain answer

The evidence is suggestive but not decisive. ATT=+8.614e+04, p=0, N=260, treated_countries=1; claim direction ambiguous

why it matters

This matters because regulatory claims should change belief only when they survive a pre-declared empirical test.

how the test works

It compares 9 country or place units from 1995 to 2024, using a did callaway santanna design, with fixed effects for country and year.

what was measured
What changed
  • Eu precautionary regulation event
What we checked
  • Citizen protection proxy gdpr reach ai act
  • Compliance cost index
  • Product launch timing eu vs us
what this does not prove

A single test is not the whole truth. It narrows the claim under a specific sample, time period, and method. Strong policy conclusions need the pattern to survive nearby tests, alternative data, and serious objections.

verification

No evidence packet has been generated yet.

Results

engine/runs/precautionary_regulation_innovation_productivity_gap_eu_us
1007550250199520102024USADEUFRAGBRIRLSWEESP
illustrative sketch · run pending
No coefficients yet. When the model fires, this chart will show citizen_protection_proxy_gdpr_reach_ai_act across 9 sampled countries over 1995–2024.
The shapes above are stylised — none of the lines are real data.
Placeholder for precautionary_regulation_innovation_productivity_gap_eu_us. Published chart will be generated from engine/runs/precautionary_regulation_innovation_productivity_gap_eu_us/chart_data.json.

Who has skin in the game — schools predicting on this

17 schools list this hypothesis as a test of their position. The chips below are school-level scoreboard outcomes, not a second hypothesis verdict.

hypothesis verdict vs scoreboard outcome

The banner verdict judges this hypothesis as written. The scoreboard asks whether each school's polarity-corrected prediction was right. Raw status is not a school win: SUPPORTED supports schools that needed SUPPORTED, but refutes schools that needed REFUTED.

Austrian Business Cycle Theory (ABCT)wins if SUPPORTEDpartial/no-callChicago School Monetarismwins if SUPPORTEDpartial/no-callClassical Liberalwins if SUPPORTEDpartial/no-callDegrowth / Ecological Macroeconomicswins if REFUTEDpartial/no-callDemocratic Socialism (Bernsteinian revisionism + modern)wins if REFUTEDpartial/no-callStructuralist / Developmentalistwins if MIXEDpartial/no-callEco-Socialism / Red-Greenwins if REFUTEDpartial/no-callEmpirical Pragmatist (the framework's house position)wins if MIXEDpartial/no-callNew Institutional Economicswins if MIXEDpartial/no-callMarket Socialism (Lange-Lerner tradition)wins if REFUTEDpartial/no-callMarxian Political Economywins if REFUTEDpartial/no-callMarxism-Leninism (central-planning implementation)wins if REFUTEDpartial/no-callModern Monetary Theorywins if REFUTEDpartial/no-callNew Keynesian (mainstream synthesis)wins if MIXEDpartial/no-callOrdoliberalism (Freiburg School)wins if SUPPORTEDpartial/no-callPost-Keynesianwins if REFUTEDpartial/no-callSocial Democraticwins if REFUTEDpartial/no-call

Pre-registration

pre-registered
first-spec commit bae09ab · 2026-04-29T22:09:42Z
run generated · 2026-04-30T13:28:09Z

Precautionary-principle-based regulation in the EU produces a three-order causal chain relative to the US regulatory baseline. FIRST-ORDER: environmental, privacy, consumer-safety, and pharma- safety protections are codified and (largely) enforced — citizens receive measurable protection from harms targeted by each regulation (REACH substances registered; GDPR breach notifications required; AI Act high-risk systems audited; EMA pharma-safety signals maintained). This is an acknowledged policy success for citizens. SECOND-ORDER: compliance costs rise, especially for small and medium firms; EU single-market fragmentation persists because member states transpose differentially; product-launch timing in the EU lags the US. THIRD-ORDER: R&D investment and firm formation relocate (pharmaceutical product launches in US then EU; AI and biotech unicorn formation; venture funding per capita gap); EU-US productivity and per-capita income gap widens. Cases: GDPR 2018, REACH 2007-2018, AI Act 2024, EMA vs FDA drug approval timing, Digital Markets Act / Digital Services Act 2022- 2024.

Falsification criterion — what would disprove this

set before the run · honoured after

This hypothesis is considered falsified if:

Not supported if, across the outcome set: (a) FIRST-ORDER protection delivery is confirmed at p<0.05 (acknowledged success) AND (b) once capital-market-depth, bankruptcy-regime, and high-skill immigration controls are included, the EU-vs-US DiD coefficient on firm-formation, R&D, VC, TFP becomes non-significant (p>0.10). If the productivity/firm-formation gap is fully absorbed by NON-regulatory controls, the chain claim is refuted even though the protections (1st-order) are delivered.

formal test & threshold
test:      eu_us_did_with_non_regulatory_controls_causal_chain
threshold: FIRST-ORDER citizen protection delivered AND RESIDUAL regulatory coefficient on at least 3 of 4 third-order outcomes (firm formation, R&D, VC, TFP) significant at p<0.05 AFTER controlling for capital-market depth, bankruptcy regime, and immigration

Method

Template
did_callaway_santanna
Fixed effects
country, year
Clustering
country
Sample
9 countries · 1995 – 2024
Evidence type
causal

Primary: Callaway-Sant'Anna DiD across the GDPR May-2018 and REACH staged-registration events, with US as untreated counterfactual. Secondary: panel FE on cumulative regulatory- stock index against outcomes. The EU-vs-US comparison is the central identification; results must be reported with a capital-market-depth control that absorbs the non-regulatory contribution to the gap.

Data

VariableSourceTransform
citizen_protection_proxy_gdpr_reach_ai_act
outcome
constructed:data-breach notification rate (GDPR); REACH-registered substances count; AI Act high-risk audits; EMA pharmacovigilance tier 5
index
compliance_cost_index
outcome
constructed:compliance-cost surveys from CEPS, Bruegel, EU Regulatory Fitness reports + CRA estimates for REACH and AI Acttier 5
log_real_eur_per_firm
product_launch_timing_eu_vs_us
outcome
ema_fda_comparative:drug_approval_datestier 3
it_product:gdpr_feature_launch_gaptier 3
days_lag
unicorn_and_high_growth_firm_count
outcome
cbinsights:unicorn_trackertier 3
pitchbook:VC_funded_firmstier 3
crunchbase:firm_registrytier 3
count_per_million_population
rd_investment_per_gdp
outcome
eurostat:rd_e_gerdregtier 1
oecd:research_and_development_statisticstier 2
pct_gdp
productivity_level_tfp
outcome
eu_klems:tfptier 3
bls:multifactor_productivitytier 1
index_2005_100
venture_capital_per_capita
outcome
invest_europe:venture_capital_statisticstier 3
nvca:venture_capital_monitor (US)tier 3
log_real_usd_per_capita
eu_precautionary_regulation_event
treatment
constructed:event indicators (GDPR May-2018, REACH 2007 + registration deadlines 2010/2013/2018, AI Act adoption 2024, DMA/DSA 2023-tier 5
indicator
capital_market_depth
control
imf:FSItier 2
world_bank_wdi:market_cap_to_gdptier 2
pct_gdp
bankruptcy_regime_stringency
control
world_bank_wdi:doing_businesstier 2
oecd:business_dynamicstier 2
index
immigration_high_skill_share
control
oecd:international_migration_outlooktier 2
pct_of_labour_force

● ready  · ● pending  · ● reconstruct-needed

Detailed result card

Result card — precautionary_regulation_innovation_productivity_gap_eu_us

Verdict: PARTIAL — ATT=+8.614e+04, p=0, N=260, treated_countries=1; claim direction ambiguous

Pre-registration

  • Claim: Precautionary-principle-based regulation in the EU produces a three-order causal chain relative to the US regulatory baseline. FIRST-ORDER: environmental, privacy, consumer-safety, and pharma- safety protections are codified and (largely) enforced — citizens receive measurable protection from harms targeted by each regulation (REACH substances registered; GDPR breach notifications required; AI Act high-risk systems audited; EMA pharma-safety signals maintained). This is an acknowledged policy success for citizens. SECOND-ORDER: compliance costs rise, especially for small and medium firms; EU single-market fragmentation persists because member states transpose differentially; product-launch timing in the EU lags the US. THIRD-ORDER: R&D investment and firm formation relocate (pharmaceutical product launches in US then EU; AI and biotech unicorn formation; venture funding per capita gap); EU-US productivity and per-capita income gap widens. Cases: GDPR 2018, REACH 2007-2018, AI Act 2024, EMA vs FDA drug approval timing, Digital Markets Act / Digital Services Act 2022- 2024.
  • Falsification rule: Not supported if, across the outcome set: (a) FIRST-ORDER protection delivery is confirmed at p<0.05 (acknowledged success) AND (b) once capital-market-depth, bankruptcy-regime, and high-skill immigration controls are included, the EU-vs-US DiD coefficient on firm-formation, R&D, VC, TFP becomes non-significant (p>0.10). If the productivity/firm-formation gap is fully absorbed by NON-regulatory controls, the chain claim is refuted even though the protections (1st-order) are delivered.

Estimate (Callaway-Sant'Anna staggered DiD, TWFE approximation)

  • coefficient: 86139.30650244371
  • std_error: 1362.1651273325301
  • p_value: 0.0
  • n_obs: 260
  • n_countries: 9
  • r_squared_within: 0.9548380912384111
  • fe_entity: True
  • fe_time: True
  • cluster: country
  • method: Callaway-Sant'Anna TWFE fallback (linearmodels failed: No module named 'linearmodels')
  • n_treated_countries: 1
  • cohort_years: [2018]
  • dropped_controls_due_to_overlap: []

Variables resolved

  • eurostat:rd_e_gerdreg; oecd:research_and_development_statistics → rd_investment_per_gdp (outcome, n=11871)

Missing data

  • constructed: data-breach notification rate (GDPR); REACH-registered substances count; AI Act high-risk audits; EMA pharmacovigilance signals (outcome)
  • constructed: compliance-cost surveys from CEPS, Bruegel, EU Regulatory Fitness reports + CRA estimates for REACH and AI Act (outcome)
  • ema_fda_comparative:drug_approval_dates (historical FDA-EMA lag studies, Tufts CSDD); it_product:gdpr_feature_launch_gap (Apple, Google, Meta feature rollout deltas) (outcome)
  • cbinsights:unicorn_tracker; pitchbook:VC_funded_firms; crunchbase:firm_registry (outcome)
  • eu_klems:tfp; us_bls:multifactor_productivity (outcome)
  • invest_europe:venture_capital_statistics; nvca:venture_capital_monitor (US) (outcome)
  • constructed: event indicators (GDPR May-2018, REACH 2007 + registration deadlines 2010/2013/2018, AI Act adoption 2024, DMA/DSA 2023-2024); EU-vs-US indicator as the cross-sectional treatment (treatment)
  • imf:FSI; world_bank:market_cap_to_gdp (controls)
  • world_bank:doing_business (historical); oecd:business_dynamics (controls)
  • oecd:international_migration_outlook (controls)

Generated by scripts/run_did_callaway_santanna.py at 2026-04-30T13:28:09+00:00

Strongest opposing argument

Every hypothesis ships with its charitable opposing argument. The framework earns credibility by handling objections at their strongest, not weakest.

Notes

Chain: protection delivered (1st) -> compliance cost + launch-lag (2nd) -> R&D, firm formation, VC, TFP gap (3rd). Falsification rests on whether residual regulatory coefficient survives non-regulatory controls.

Authored framework. Read the transparency note.